GB 1
Alternative Names: GB1Latest Information Update: 28 Jul 2024
At a glance
- Originator Denali Therapeutics Inc
- Class Antidementias; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
- Discontinued Alzheimer's disease
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA (PO)
- 31 Dec 2019 GB 1 is available for licensing as of 31 Dec 2019. https://denalitherapeutics.com/partnering